Investor Relations
Company Overview
X4 is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases. X4’s pipeline is comprised of first-in-class, oral, small molecule antagonists of chemokine receptor CXCR4, which have the potential to treat a broad range of rare diseases, including primary immunodeficiencies, neutropenia, and certain cancers.
Jul 5, 2022 8:41 AM EDT
Copyright Refinitiv
Minimum 15 minutes delayed.
Refresh Quote
Copyright Refinitiv
Minimum 15 minutes delayed.
Press Releases
July 1, 2022
June 30, 2022
May 16, 2022
Events
May 12, 2022 at 8:30 AM EDT
Apr 14, 2022 at 10:30 AM EDT
Apr 11, 2022 at 3:45 PM EDT
Presentations
X4 Investor Deck May 2022
X4 Investor Deck May 2022 4.8 MB
ASH 2021: X4 Understanding Primary Immunodeficiencies Event
ASH 2021: X4 Supplemental Waldenström’s Macroglobulinemia Slides
X4 Pharmaceuticals EHA 2021 Corporate Update Presentation
X4 Pharma Post-EHA Corporate Update Presentation